Education
About Us
Working with TipRanks
Follow Us
Pharming Group Nv (PHAR)
:PHAR
PHAR Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PHAR Stock 12 Month Forecast
Average Price Target
$30.33
▲(117.11% Upside)
| Highest Price Target$41.00 | Average Price Target$30.33 | Lowest Price Target$13.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$13
Hold
-6.94%
Downside
Reiterated
08/23/25
Oppenheimer
$41
Buy
193.49%
Upside
Reiterated
08/01/25
H.C. Wainwright
$37
Buy
164.85%
Upside
Reiterated
08/01/25
Pharming Group's Strong Financial Performance and Strategic Developments Justify Buy RatingValuation and risks to achieving it. We reiterate our Buy rating and $37 price target on the U.S.-traded ADRs of Pharming. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Ruconest contributes 48% to our valuation and Joenja contributes 52%. We look to add KL1333 to our valuation in the future, representing potential significant upside, whereas now we believe the company is undervalued on the Ruconest and Joenja opportunities alone.
Jefferies
$14
Buy
0.21%
Upside
Initiated
12/09/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$13
Hold
-6.94%
Downside
Reiterated
08/23/25
Oppenheimer
$41
Buy
193.49%
Upside
Reiterated
08/01/25
H.C. Wainwright
$37
Buy
164.85%
Upside
Reiterated
08/01/25
Pharming Group's Strong Financial Performance and Strategic Developments Justify Buy RatingValuation and risks to achieving it. We reiterate our Buy rating and $37 price target on the U.S.-traded ADRs of Pharming. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Ruconest contributes 48% to our valuation and Joenja contributes 52%. We look to add KL1333 to our valuation in the future, representing potential significant upside, whereas now we believe the company is undervalued on the Ruconest and Joenja opportunities alone.
Jefferies
$14
Buy
0.21%
Upside
Initiated
12/09/24
Best Analysts Covering Pharming Group
1 Month
xxx
Success Rate
6/12 ratings generated profit
Average Return
+4.18%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.18% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
Average Return
+9.22%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.22% per trade.
1 Year
Success Rate
10/12 ratings generated profit
Average Return
+33.86%
reiterated a buy rating 28 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +33.86% per trade.
2 Years
xxx
Success Rate
12/12 ratings generated profit
Average Return
+48.28%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +48.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PHAR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
5
3
2
3
Buy
0
0
0
0
1
Hold
5
5
6
7
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
9
9
13
Each month's total comprises the sum of three months' worth of ratings.
PHAR Financial Forecast
PHAR Stock Forecast FAQ
What is PHAR’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharming Group Nv’s 12-month average price target is 30.33.
What is PHAR’s upside potential, based on the analysts’ average price target?
Pharming Group Nv has 117.11% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PHAR a Buy, Sell or Hold?
Pharming Group Nv has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Pharming Group Nv’s price target?
The average price target for Pharming Group Nv is 30.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $13.00. The average price target represents 117.11% Increase from the current price of $13.97.
The highest analyst price target is $41.00 ,the lowest forecast is $13.00. The average price target represents 117.11% Increase from the current price of $13.97.
What do analysts say about Pharming Group Nv?
Pharming Group Nv’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of PHAR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.